The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

By S. Solomon, M. Zile, B. Pieske, A. Voors, A. Shah, E. Kraigher‐Krainer, V. Shi, T. Bransford, M. Takeuchi, J. Gong and 3 more. The Lancet, 2012

1,037 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/05825fd6edda157545eaf4f6d3dfb0b54d393838

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. W. Paulus
2. C. Tschöpe

In Surgery

1. W. Paulus

Citations in the corpus

• A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. (2013, result): “This failure relates to the low diastolic wall stress prevailing in a concentrically remodeled left ventricle (39), is consistent with the lower BNP levels frequently observed in HFPEF patients (20,40), and supports use in HFPEF of neprilysin inhibition to reduce BNP breakdown (41).”